Format
Sort by
Items per page

Send to

Choose Destination

Best matches for gla parkinson's:

Search results

Items: 1 to 20 of 31

1.

Association of Low Lysosomal Enzymes Activity With Brain Arterial Dilatation: A Pilot Study.

Shah H, Liong C, Levy OA, Waters C, Fahn S, Marder K, Kang UJ, Wolf P, Oliva P, Zhang K, Alcalay RN, Gutierrez J.

Stroke. 2018 Jul 9. pii: STROKEAHA.118.021964. doi: 10.1161/STROKEAHA.118.021964. [Epub ahead of print]

PMID:
29986930
2.

Parkinson's disease prevalence in Fabry disease: A survey study.

Wise AH, Yang A, Naik H, Stauffer C, Zeid N, Liong C, Balwani M, Desnick RJ, Alcalay RN.

Mol Genet Metab Rep. 2017 Nov 9;14:27-30. doi: 10.1016/j.ymgmr.2017.10.013. eCollection 2018 Mar.

3.

[Glabridin attenuates MPTP-induced parkinson disease by inhibiting extracellular regulated protein kinases signaling pathway].

Zhao Y, Lu ZN.

Zhonghua Yi Xue Za Zhi. 2017 Jul 11;97(26):2050-2054. doi: 10.3760/cma.j.issn.0376-2491.2017.26.008. Chinese.

PMID:
28763878
4.

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.

Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, Vockley G, Hamazaki T, Lachmann R, Ohashi T, Olivotto I, Sakai N, Deegan P, Dimmock D, Eyskens F, Germain DP, Goker-Alpan O, Hachulla E, Jovanovic A, Lourenco CM, Narita I, Thomas M, Wilcox WR, Bichet DG, Schiffmann R, Ludington E, Viereck C, Kirk J, Yu J, Johnson F, Boudes P, Benjamin ER, Lockhart DJ, Barlow C, Skuban N, Castelli JP, Barth J, Feldt-Rasmussen U.

J Med Genet. 2017 Apr;54(4):288-296. doi: 10.1136/jmedgenet-2016-104178. Epub 2016 Nov 10. Erratum in: J Med Genet. 2018 Apr 16;:.

5.

Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease.

Pchelina S, Emelyanov A, Baydakova G, Andoskin P, Senkevich K, Nikolaev M, Miliukhina I, Yakimovskii A, Timofeeva A, Fedotova E, Abramycheva N, Usenko T, Kulabukhova D, Lavrinova A, Kopytova A, Garaeva L, Nuzhnyi E, Illarioshkin S, Zakharova E.

Neurosci Lett. 2017 Jan 1;636:70-76. doi: 10.1016/j.neulet.2016.10.039. Epub 2016 Oct 22.

PMID:
27780739
6.

Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration.

Janssen CI, Kiliaan AJ.

Prog Lipid Res. 2014 Jan;53:1-17. doi: 10.1016/j.plipres.2013.10.002. Epub 2013 Oct 24. Review.

PMID:
24334113
7.

Genetic analysis of lysosomal alpha-galactosidase A gene in sporadic Parkinson's disease.

Wu G, Pang S, Feng X, Zhang A, Li J, Gu K, Huang J, Dong H, Yan B.

Neurosci Lett. 2011 Aug 1;500(1):31-5. doi: 10.1016/j.neulet.2011.05.238. Epub 2011 Jun 12.

PMID:
21683120
8.

Decreased expression of lysosomal alpha-galactosiase A gene in sporadic Parkinson's disease.

Wu G, Huang J, Feng X, Zhang A, Li J, Pang S, Gu K, Dong H, Zhang J, Gao H, Yan B.

Neurochem Res. 2011 Oct;36(10):1939-44. doi: 10.1007/s11064-011-0516-0. Epub 2011 Jun 5.

PMID:
21643977
9.

Investigating variability in patient response to treatment--a case study from a replicate cross-over study.

Senn S, Rolfe K, Julious SA.

Stat Methods Med Res. 2011 Dec;20(6):657-66. doi: 10.1177/0962280210379174. Epub 2010 Aug 25.

PMID:
20739334
10.
11.
12.

Therapy adherence issues in Parkinson's disease.

Grosset D; European PD Therapy Compliance Study Group.

J Neurol Sci. 2010 Feb 15;289(1-2):115-8. doi: 10.1016/j.jns.2009.08.053. Epub 2009 Sep 29. Review.

PMID:
19793590
13.

Dopamine agonists and therapy compliance.

Grosset D.

Neurol Sci. 2008 Dec;29 Suppl 5:S375-6. doi: 10.1007/s10072-008-1050-y. Review.

PMID:
19381766
14.

Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT.

Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, Benamer HT, Kemp P, Burn D, Tolosa E, Kulisevsky J, Cunha L, Costa D, Booij J, Tatsch K, Chaudhuri KR, Ulm G, Pogarell O, Höffken H, Gerstner A, Grosset DG.

Mov Disord. 2009 Mar 15;24(4):500-8. doi: 10.1002/mds.22108.

PMID:
19117369
15.

Timing the initiation of treatment in Parkinson's disease.

Grosset DG, Schapira AH.

J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):615. doi: 10.1136/jnnp.2008.144741. No abstract available.

PMID:
18487552
16.

Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging.

Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG.

Nucl Med Commun. 2006 Dec;27(12):933-7.

PMID:
17088677
17.

Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT.

Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG.

Mov Disord. 2006 Dec;21(12):2247-50.

PMID:
17078059
18.

Problematic gambling on dopamine agonists: Not such a rarity.

Grosset KA, Macphee G, Pal G, Stewart D, Watt A, Davie J, Grosset DG.

Mov Disord. 2006 Dec;21(12):2206-8.

PMID:
17013907
19.

Measuring therapy adherence in Parkinson's disease: a comparison of methods.

Grosset KA, Bone I, Reid JL, Grosset D.

J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):249-51.

20.

Keynote review: phosphodiesterase-4 as a therapeutic target.

Houslay MD, Schafer P, Zhang KY.

Drug Discov Today. 2005 Nov 15;10(22):1503-19. Review.

PMID:
16257373

Supplemental Content

Loading ...
Support Center